The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...
News Medical on MSN3h
Sotagliflozin could be used to reduce the risk of deadly cardiovascular events, trial showsSotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.
CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...
A team of researchers, led by one of Indian origin, has found that a drug recently approved by the US Food and Drug Administ ...
A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...
News Medical on MSN16h
A step toward precision medicine: New drug targets for heart failureA groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...
GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...
Sotagliflozin belongs to a class of medications called gliflozins that help lower blood sugar levels by preventing the ...
Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback